title: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of oral ondansetron (Zofran) as an antiemetic in patients receiving cyclophosphamide-based chemotherapy.
  
  
  METHODS
  A multicenter, randomized, double-blind, stratified, placebo-controlled trial conducted between March 1989 and January 1990.
  
  
  METHODS
  Twenty-seven oncology centers including university hospitals, community cancer centers, and private medical oncology practices.
  
  
  METHODS
  A total of 349 chemotherapy-naive patients having their first cycle of cyclophosphamide (> or = 450 mg/m2)-based chemotherapy. Patients also received methotrexate (> or = 30 mg/m2) or doxorubicin (> or = 35 mg/m2). All patients were evaluated for safety and 318 (91%) were evaluated for efficacy.
  
  
  METHODS
  Patients were randomly assigned to one of four treatment groups: placebo, 1 mg, 4 mg, or 8 mg of ondansetron. Assigned study medication was taken three times per day for 3 consecutive days.
  
  
  METHODS
  Time and number of emetic episodes as well as degree of nausea were recorded by patients for each of the 3 study days.
  
  
  RESULTS
  Compared with placebo, all three doses of ondansetron were superior (P < 0.001) in preventing vomiting and controlling nausea. A complete response (no emetic episodes) was observed in 19%, 57%, 65%, and 66% of patients in the placebo, 1-mg, 4-mg, and 8-mg ondansetron groups, respectively. For patients who received higher-dose cyclophosphamide and doxorubicin, a dose-related trend in antiemetic efficacy of ondansetron was observed. Mild headache and constipation were the most frequently reported adverse events. No extrapyramidal reactions were observed.
  
  
  CONCLUSIONS
  Oral ondansetron is a safe and effective antiemetic that is more efficacious than placebo for patients receiving cyclophosphamide-based chemotherapy.
authors.affiliation: Mountain States Tumor Institute, Boise, Idaho 83712-6297.
authors.forename: T M
authors.initials: TM
authors.lastname: Beck
authors.forename: A A
authors.initials: AA
authors.lastname: Ciociola
authors.forename: S E
authors.initials: SE
authors.lastname: Jones
authors.forename: W H
authors.initials: WH
authors.lastname: Harvey
authors.forename: N S
authors.initials: NS
authors.lastname: Tchekmedyian
authors.forename: A
authors.initials: A
authors.lastname: Chang
authors.forename: D
authors.initials: D
authors.lastname: Galvin
authors.forename: N E
authors.initials: NE
authors.lastname: Hart
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003520:Cyclophosphamide / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D017294:Ondansetron / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D017294:Ondansetron; D003520:Cyclophosphamide